AT1 receptor is present in glioma cells; its blockage reduces the growth of rat glioma by Rivera, E et al.
Angiotensin II (AgII) participates on cellular proliferation and
angiogenesis (Fernández et al, 1985; Chung et al, 1998; Fournier
et al, 1999) through the Angiotensin II receptor 1 (AT1R), whereas
the Angiotensin II receptor 2 (AT2R) has a counterregulatory effect
(Stoll et al, 1995a, 1995b). The administration of angiotensin
converting enzyme inhibitors (ACEI) and AT1R antagonists
(AT1RA) block this signal (Burnier, 2001; Stoll et al, 1995a; Wang
and Prewitt, 1990; Hafizi et al, 1998). Although the mechanisms
involved in the effects mediated by AT1R have not been elucidated
it has been found that the stimulation of the receptor increases the
transcription of growth-related factors. This mechanism is partly
mediated by the platelet-derived growth factor (PDGF) (Wang et
al, 1999). 
In humans, glioma is the most frequent brain tumour
(DeAngelis, 2001). Malignant gliomas show extensive prolifera-
tion of vascular endothelium and angiogenesis, essential for
tumoral growth and invasiveness. Tumour endothelial cells play
an active role in angiogenesis through secretion of growth factors,
such as PDGF, vascular endothelial growth factor (VEGF), trans-
forming growth factor (TGFβ ), epidermal growth factor (EGF),
hepatocyte growth factor/scatter factor (HGF/SF), basic fibroblast
growth factor (bFGF), tumour necrosis factor (TNFα ) and angio-
genin (Jensen, 1998; Schmidt et al, 1999). The interactions of
these factors are poorly understood. 
A therapeutic possibility in the treatment of cancer is through
inhibition of angiogenesis (Arrieta et al, 1998). The present inves-
tigation was directed first to search for the AT1R on C6 glioma
cells; then, by the use of Losartan (C22H22CIKN6O), a substance
with selective affinity for AT1R, we measured its effect on angio-
genesis and tumour growth on C6 rat glioma. 
MATERIAL AND METHODS 
C6 rat glioma cells (American Tissue Culture Collection,
Rockville, Maryland, USA) were cultured at 37˚C under sterile
conditions in Ham’s F-10 medium supplemented with 2.5% fetal
calf serum and 15% horse serum. For induction of C6 rat glioma 
1 × 107 cultured C6 cells were inoculated intraperitoneally in a 12-
week-old Wistar rat; 20 days later, a large, multilobulated peritoneal
tumour developed. The tumour was mechanically dissociated at
4˚C; a suspension of 1 × 107 cells in 500 µ l of saline solution was
subcutaneously inoculated into the left thigh of 12-week-old female
Wistar rats as previously described (Guevara and Sotelo, 1999). A
subcutaneous tumour developed in 80% of the animals, it reached a
diameter of 1.5 cm 19–21 days after cell implantation (Guevara and
Sotelo, 1999). 
Search for AT1R in C6 cells was made by RNA extraction and
reverse transcriptase-polymerase chain reactions (RT-PCR). Total
RNA was obtained (Chamczynski and Sacchi, 1987) and processed
by electrophoresis on formaldehyde-containing agarose gels and
visualization with UV light using ethidium bromide staining. RT-
PCR were performed with total RNA (Perking Elmer, USA), the
primers corresponding to bases 133–150 and 739–719 of the rat
AT1 receptor cDNAs (Iwai and Inagami, 1992). The PCR amplifi-
cation profile consisted of denaturation at 95˚C for 30s, primer
annealing at 60˚C for 60s and extension at 72˚C for 90s (28 cycles)
using 5 µ g total RNA (González-Espinoza and Garcia-Sainz,
1992). The RT-PCR products were electrophorized in 7.5% poly-
acrylamide gels. 
Thirty-seven rats with subcutaneous glioma 1.5 cm diameter
were randomly allocated to one of 3 groups: group A controls 
(n = 12), received orally 0.3 ml of saline daily for 30 days. Group B
(n = 13) received 40 mg/kg of Losartan (Merck-Sharp & Dome
Pharmaceutics) orally, once a day, for 30 days. Group C (n = 12)
received Losartan 80 mg/kg per day at the same schedule. After 30
days of treatment, all animals were anaesthetized with ether and
perfused by intracardiac route with 10% formalin in saline solu-
tion for histological study. Before perfusion, the animals were bled
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by intracardiac puncture to study haematological and chemical
blood parameters, body weight of animals from all groups
remained similar throughout the experiment. The tumour was
dissected and its volume determined by water displacement. All,
animals used in this study, were handled in accordance to the
guidelines of the United Kingdom co-ordinating committee on
cancer research (UKCCR) for the welfare of animals in experi-
mental neoplasia (Second Edition) (Workman et al, 1998). For
microscopic study the tumour was embedded in paraffin; 10 µ m
sections were stained with haematoxylin and eosin. Immuno-
histochemistry with rabbit antibodies to factor VIII R (Harris,
1997) (Sigma), as marker for vascular endothelial cells was used to
identify tumour vasculature. Tissue slices of 5 µ m were treated
with 5% trypsin, washed and incubated with antiserum to factor
VIII R for 1 h at 37˚C, followed by incubation with goat antirabbit
antibodies conjugated with fluorescein. Sections of rat tongue
were used as positive controls. Microvessel density was deter-
mined by light microscopy in areas of tumour viability (at the
periphery of the tumour) containing the highest numbers of capil-
laries and small venules (microvessels) per area. These neovas-
cular ‘hotspots’ were detected by scanning the tumour sections at
low power (40 × and 100 × ) and identifying areas having the
greatest number of distinct Factor VIII-related antigen-staining
microvessels per area. Individual microvessel counts were then
made on a 200 × field (× 20 objective and × 10 ocular; equivalent
to 0.7386 mm2 per 200 × field) within the neovascular hotspot for
each tumour. Any endothelial cell or endothelial cell cluster posi-
tive for Factor VIII-related antigen and clearly separate from
an adjacent cluster was considered to be a single, countable
microvessel. Results were expressed as the highest number of
microvessels identified within any single 200 × field (Weidner 
et al, 1991; Roychowdnury et al, 1996). Cell proliferation was
studied by immunohistochemistry with monoclonal antibodies
against the proliferation nucleocellular antigen (Sigma, St Louis
Missouri, USA). The cell proliferation index was obtained by the
mean of positive cells in ten different microscopic fields. All histo-
logical evaluations (40 × ) were made without knowledge of the
group source of the specimen. Comparisons between groups were
made Tukey Test and expressed as means ± standard error (SE);
statistical significance was set at 5% level. 
RESULTS 
An AT1R fragment of ≈ 600 bp in C6 glioma cells was detected by
RT-PCR (Figure 1, lanes 4 and 7). No such fragments were
detected in the absence of reverse transcriptase (Figure 1, lanes
3,5,6). The fragment had the size expected, comparable to that
obtained using RNA from rat liver (Iwai and Inagami, 1992). 
Administration of Losartan showed a dose dependent reduction
in tumoural volume. The mean tumour volume in controls
was 51.6 ± 6.4 cc; whereas in animals treated with Losartan
80 mg/kg/d the volume was 11.4 ± 4.4 cc (P < 0.01), and in those
treated with Losartan 40 mg/kg/d the volume was 31.53 ± 6.9 cc
(P < 0.025 when compared with controls and P < 0.01 when
compared with the 80 mg/kg/d group). In rats treated with
Losartan at 80 mg/kg/d and 40 mg/kg/d a 79% and 39% reduction
of tumour size was obtained, respectively (Figure 2). 
In controls the mitotic index in viable areas of tumour was 3.12
± 0.14; whereas in animals treated with Losartan at doses of
80 mg/kg/d and 40 mg/kg/d it was 1.42 ± 0.12 (P < 0.01) and 1.7 ±
0.09 (P < 0.01 when compared with controls). The cell prolifera-
tion index in tumours from animals treated with Losartan
80 mg/kg/d and 40 mg/kg/d was 39.3 ± 3.5 and 43.8 ± 2.7 respec-
tively (P < 0.05); in controls it was 61.2 ± 2.8 (P < 0.01 when
compared with the experimental groups). The mean number of
capillary vessels in tumours from animals treated with Losartan 80
and 40 mg/kg/d was 8.05 ± 0.8 and 10.02 ± 0.5 respectively; in
controls it was 14.31 ± 0.81 (P < 0.001 when compared with the
experimental groups), (Figure 2). 
Comparisons of haematological and chemical blood parameters
measured at the end of the study showed no differences between
groups. No mortality was seen during the experiment. 
DISCUSSION 
Our results demonstrated the presence of AT1 receptors in C6
glioma cells; also, the selective blockage of this receptor in exper-
imentally induced C6 glioma reduces angiogenesis and growth.
The only clinical precedent to this finding is an apparent low
cancer incidence in hypertensive patients receiving ACEI (Lever
et al, 1998). Besides its anti-angiogenic activity, Losartan is a
blocking agent of cellular signals mediated by AgII; it has a poten-
tial antitumoural effect in SH-SY5Y human neuroblastoma cells
by inhibition of Angiotensin-converting enzyme and reduction of
thymidine incorporation on DNA dependent of AgII (Chen et al,
1991). Our results suggest a similar effect in experimental glioma. 
Tumour-induced angiogenesis is a complex phenomenon. In
human and experimental glial tumours many cytokines, such as
VEGF, PDGF, bFGF, EGF, TNFα and TGF α and β participate in
tumour angiogenesis (Lund et al, 1998; Plate et al, 1994a; van der
Valk et al, 1997), interestingly, the presence of these cytokines in
normal brain is minimal. There is evidence of autocrine and
paracrine loops (tumour to tumour, tumour to endothelial cells
and endothelial cells to tumour) between these growth factors,
Figure 1 RT-PCR of the reaction products for the AT1 receptor. Lanes 2
and 6 correspond to the negative control with GADPH in the absence of
reverse transcriptase; lanes 8 and 10 correspond to AT1R fragments in the
absence of reverse transcriptase, lanes 1,3 and 5 correspond to negative
controls with GADPH in the presence of reverse transcriptase; lanes 4 and 7
correspond to AT1R fragments in the presence of reverse transcriptase of
≈ 600 bp present in C6 glioma cells and lanes 9 and 11 correspond to the
negative control and the molecular weight marker with 1353 bp respectively 1398 E Rivera et al
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particularly PDGF-B/PDGFR (van der Valk et al, 1997), which has
been recognized as a growth stimulant for glial cells (Plate et al,
1994a). Aside from promotion of angiogenesis in C6 glioma cells,
bFGF, PDGF and heparin binding-EGF increase DNA synthesis.
Also, it has been shown that VEGF is highly expressed in glioblas-
toma multiforme cells, specially around necrotic areas, and flt-1 and
flk-1 receptors are abundantly present in endothelial cells from
highly malignant gliomas, but not in the normal brain (Plate et al,
1994b). Moreover, VEGF is among the most important mediators
of angiogenesis, as shown by the diminution of tumoural growth
and angiogenesis after the blockage of this cytokine, either with
monoclonal antibodies or with antisense RNA (Kim et al, 1993;
Cheng et al, 1996). A similar effect was seen by anti-bFGF anti-
bodies on human glioma cells implanted on nude mice (Lund et al,
1998). 
Increase of cell proliferation mediated by AT1 has not been
described, although the stimulation of its receptor increases tran-
scription of growth-related factors like c-fos,  c-myc and  c-jun
(Kawakara et al, 1988); and growth-related cytokines like PDGF,
bFGF and TGF. In cultured smooth muscle cells treated with
AT2 the PDGF-A chain levels increase, as well as the production
of PDGF-AA and transforming growth factor 1 (TGF-1) (Dzait
et al, 1991). Furthermore, PDGF induces release of VEFG in
endothelial cells. This mechanism is activated during periods of
angiogenesis on inflammation and glial tumourigenesis (Wang et
al, 1999). 
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Figure 2 Comparisons of tumour volume, vascular density, mitotic index and cellular proliferation index in rats with a C6 glioma treated with Losartan at doses
of 40 or 80 mg/kg/d and controls The presence of AT1 receptor on C6 glioma cells may induce the
production of PDGF, bFGF, VEGF and TGF1; in turn, it seems
likely that the inhibition of this biochemical pathway with Losartan
was responsible for the observed decrease of cell proliferation in
C6 malignant glioma. Losartan might also induce apoptosis in
malignant glial cells by mechanisms similar to those described in
other cells (Siragy, 1999). Moreover, the blockade of AT1 induced
by Losartan, could also increase the bioavailability of Angiotensin
II (by reducing the inhibitory effect on rennin secretion by the
AT1R) producing upregulation and an overstimulation of the AT2
receptor, which in turn could potentate the anti-proliferative effects
of Losartan. Because the AT1R has also been found in normal
astrocytes (Leung et al, 1992) and Losartan penetrates the blood-
brain-barrier its effect would be exerted in endothelial cells, as well
as in malignant glial cells. A direct effect on glial cells could also be
important since those parameters related to mitosis and cell prolif-
eration were significantly reduced (Figure 2). 
This is the first report that shows the presence of AT1 in glioma
cells, together with the potential anti-tumoural effect of the selective
blockage of AT1R disturbing the mechanisms responsible for
tumour growth and angiogenesis, which are so conspicuous in
malignant glioma. While this manuscript was initially under consid-
eration for publication a report was published showing remarkably
similar results about the presence AT1 receptors in pancreatic
cancer and inhibition of tumour growth by a receptor antagonist
(Fujimoto et al, 2001). It is important to stress the absence of drug
toxicity in this study. A clinical trial using Losartan as adjuvant
treatment for glioblastoma multiforme and other malignant tumours
seems warranted. Additional studies on the effects of Losartan on
tumour cells which lack the receptor and/or over express it are
necessary. Detection of AT1R in malignant tumours could be a
strategy for the use of AT1R blockers as part of treatment. 
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